Rapid Therapeutic Science Laboratories File S1 and completes Mid-Year Strategy Review
Rapid Therapeutics Science Laboratories (OTC: RTSL) announced its S1 filing and mid-year strategy review on July 26, 2022. CEO Donal Schmidt emphasized the company's focus on pharmaceutical R&D and aerosol technology to enhance natural relief solutions. The company aims to file an investigational new drug application (IND) for its CBD metered dose inhaler (MDI) with the FDA. Despite CBD's legal status in many states, it is not FDA-approved for consumption. RTSL remains committed to research and development in biologics while seeking a major stock exchange listing.
- Filed S1 and completed mid-year strategy review.
- Focus on pharmaceutical R&D and aerosol technology.
- Preparing to file IND with the FDA for CBD MDI.
- CBD is not FDA-approved for human consumption.
- Risks associated with IND filing and potential FDA approval.
DALLAS, July 26, 2022 (GLOBE NEWSWIRE) -- Rapid Therapeutics Science Laboratories (OTC: RTSL) ("Rapid Therapeutic'' or the "Company"), a growth-oriented aerosol manufacturing company focused on natural relief innovations through trusted aerosol delivery, announces today that it has filed it’s S1 and has completed mid-year strategy review in conjunction with the filing.
“We have and will continue to take steps towards becoming and innovative biotech company focused on natural relief solutions through trusted delivery,” Donal Schmidt, Rapid Therapeutic’s CEO said. “Our focus for the rest of the year will continue to be on our two critical strategic areas, pharmaceutical R&D on biologics and/or semisynthetic compounds and new ways to leverage applied aerosol technology while continuing efforts to list on a major stock exchange.”
The goal of this renewed focus in these critical areas is to provide RTSL with a clear focus on its day-to-day activities. This will ensure significant progress in the back half of the half of the year.
About Rapid Therapeutic Science Laboratories, Inc. (OTC Pink: RTSL)
RTSL is a biopharmaceutical company that is focused on natural relief innovations through trusted delivery. As a part of its applied aerosol technology with biologics, RTSL has developed a new method of formulating and manufacturing pressurized metered dose inhalers (pMDI) that contain and properly aerosolize proprietary formula of one or more patent pending pharmaceutical grade cannabinoid compounds. RTSL is committed to continued pharmaceutical research and development on biologics and using its applied aerosol technology. The company is preparing to file an investigational new drug application (IND) with the FDA for its CBD MDI.
Although legal for consumption in many states, CBD is not yet approved by the FDA for human or animal consumption except as a drug in prescription medication.
We encourage all individuals to do their own research regarding cannabinoids, the use of MDI and our other products. Always consult a physician prior to using any cannabinoid product. RTSL makes no therapeutic claims regarding its products, the use of its products, or any results which can be obtained from using its products. None of our products are intended to diagnose, treat, cure, or prevent any disease. If you experience any adverse reaction of any non-psychotropic cannabinoid, stop use immediately and seek appropriate medical attention. RTSL’s products are not approved by the FDA or under the Food Drug & Cosmetics Act (FD&C Act). Our products contain zero THC. Visit our corporate website at www.rtslco.com.
Forward-Looking Statements
This press release may contain forward-looking statements. In particular, when used in the preceding discussion, the words “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements. Any statements made in this news release, including statements related to the closing of the offering, other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of RTSL, its divisions and concepts to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in filings made by RTSL with the Securities and Exchange Commission, including, but not limited to, in the “Risk Factors” sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which we have filed, and file from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov.
Other unknown or unpredictable factors also could have material adverse effects on RTSL’s future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements which include, among others, statements related to the closing of the offering, the timing of the filing of patent applications, the failure to obtain patents for our products and processes, the costs associated therewith, a delay in, or the failure of, our filing of the planned IND, or the failure of the FDA to approve the IND, the outcome of studies, the planned timing of product availability, the demand for such products, and our ability to produce significant quantities of such products.
The forward-looking statements included in this press release are made only as of the date hereof. RTSL cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Investors:
CORE IR
info@rtslco.com
Media:
Jules Abraham
CORE IR
julesa@coreir.com
917-885-7378
FAQ
What recent developments has RTSL made regarding its strategy?
What is RTSL's plan for its CBD metered dose inhaler?
Is CBD approved by the FDA for consumption?
What are the potential risks associated with RTSL's forward-looking statements?
What focus areas has RTSL outlined for the remainder of the year?
